FibroBiologics, Inc. a clinical-stage biotechnology company with over 160 issued and pending patents focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has announced the filing of a patent application with the United States Patent and Trademark Office , which covers methods to improve mitochondrial performance in cells using fibroblasts.

Mitochondria are vital organelles responsible for cellular energy production through oxidative phosphorylation. Mitochondrial dysregulation is involved in the aging process and a variety of diseases, including autoimmune, neurodegenerative, metabolic, and muscular diseases. Fibroblasts, primary cells for the secretion and maintenance of connective tissue, secrete bioactive molecules such as growth factors, cytokines, and extracellular vesicles that affect the cellular microenvironment.

Modulation of mitochondrial function by local or systemic administration of fibroblasts is a novel method for the treatment of mitochondrial dysregulation – an area that is increasingly coming into focus in medical research. This novel approach has the potential to unlock new treatment options for conditions caused by mitochondrial dysfunction that contribute to the pathology of many chronic diseases.

"The use of fibroblasts to improve the microenvironment of cells by modulating mitochondrial activity has the potential to fundamentally change the treatment of chronic diseases and have a positive impact on human life expectancy," said Pete O'Heeron, founder and chief executive officer of FibroBiologics.

"There has been increased interest in the research community in using mitochondria-targeting therapies to treat chronic diseases," said Hamid Khoja, Chief Scientific Officer of FibroBiologics. "Our approach leverages the natural ability of fibroblasts to modulate mitochondrial function and potentially opens up new therapeutic strategies for the treatment of several chronic diseases."